### Building Effective Engagement

Dr Stephanie Francis

Mrs Claire Ganderton

Dr Bridget-Ann Kenny





Effective Engagement

'stakeholders work collaboratively to achieve common goals'

### Key factors for effective engagement?

- Engagement Strategy
- Shared decision making
- Good communication
- ✓ Trust
- Information Sharing
- Openness and transparency






### Working Together

# To provide people in Wales timely access to medicines

'right medicine, right person, right time'



Route of access in UK

Regulatory timelines

NICE timelines (if appropriate)

PAS or commercial arrangement

Place in current treatment pathway/comparator medicines

Estimated eligible patients

Unmet clinical need

Biomarker testing

Budgetary information (when available)

# Patient Access to Medicines 'Once for Wales'

- Pipeline medicines
- Key information

Industry

#### AWTTC/AWMSG

- Horizon scanning
- CMAT
- All-Wales Advice
- NICE Advice

- Formulary inclusion
- Planning
- Implementation

Health Boards





# Current routes for information sharing

**UK PharmaScan** 

Advanced budgetary notification

Form A

Email: awttc@wales.nhs.uk

### **Current limitations**



MHRA INFORMATION SHARING



FORM A



MONITORING NICE WORK PROGRAMME



NOT ON NICE WORK
PROGRAMME



LIMITED SHARING OF BUDGETARY INFORMATION

### AWTTC horizon scanning



Identify medicines where All Wales advice may be required



Support financial and service planning in NHS Wales





# Horizon scanning: financial planning

Significant financial impact

- >£1M net budget for Wales
- To consider additional thresholds on a per-patient basis and an individual health board/trust basis

# Horizon scanning: service planning

Significant service impact, e.g.

- Staff time/skillmix
- Clinic/pharmacy/bed/chair time
- Laboratory services, e.g.
  - Companion biomarker test (genomic/pathology-based)
  - Pharmacogenomic testing
- Radiology services

### **Timelines**




### <u>Financial</u> – to align with health board/trust annual planning

o 12-18 months horizon

<u>Service</u> – to align with HTA publication

New Treatment Fund – clock starts at FDG/FAD/FED stage

# Horizon scanning outputs



### Horizon scanning inputs



Desk work



Clinician/health board engagement



Company engagement

### Building collaborative partnerships

Welsh Health Specialised Services Committee (WHSSC)

**Advanced Therapy Wales (ATW)** 

**Medicines Value Unit (MVU)** 

**Formulary pharmacists** 

**Primary care pharmacists** 

Transforming Access to Medicines (TRAMS)

Wales Cancer Network (WCN)

All Wales Genomics
Oncology Group (AWGOG)

All Wales Medical Genomics
Service (AWMGS)

National pathology lead

National Pharmacogenomics
Group (NPGG)





### Company engagement (Wales)



As early as possible before marketing authorisation, acknowledging .....



Complexity of medicine/technology



Changing regulatory landscape



Limitations of data at certain timepoints

### Company engagement (Wales)

Regulatory submission?

NICE topic selection?

NICE scoping?

NICE evidence submission?

FDG/FAD/FED publication?

### Recent Engagement Activities



**How AWMSG and AWTTC are** 

supporting sustainability for

the NHS in Wales

## Recent Engagement Activities

The Well-being of Future Generations (Wales) Act (2015 ground-breaking legislation that aims to ensure that futu generations in Wales have at least the same quality of lif do now. Public bodies in Wales, including the All Wales I Strategy Group (AWMSG) and the All Wales Therapeuti Toxicology Centre (AWTTC) have a legal duty to take int the impact that their decisions will have on future general AWMSG and AWTTC have committed to a sustainability AWTTC has set up a Sustainability Group to support AW consider the act's 'sustainable development principle' in decision-making.

A report, "AWMSG and the Well-being of Future Genera (Wales) Act" (2022), outlines how AWMSG and AWTTC working to achieve the act's seven well-being goals throwell-being objectives. The report emphasises the import communication and collaboration with stakeholders, inclipharmaceutical industry, to reach those goals.

### How AWMSG and AWTTC support equality, diversity and inclusion

The All Wales Medicines Strats Wales Therapeutics and Toxico improve the safe use of medici that people in Wales can access cost-effective medicines when

WMSG and AWTTC also work oals of the <u>Well-Being of Futur</u> nd follow the Act's five ways of nd involvement. AWTTC involv its work, and must also make offert the diversity of the area in

AWMSG and AWTTC aim to re inclusion by:

- ensuring the AWTTC webs accessible
- holding virtual meetings of Group
- · completing equality an
- publishing AWTTC's work in commended for their high-qu standards
  - producing patient information easy-read formats



### We need your help.....

Engage with <u>@AWTTC - All Wales Therapeutics & Toxicology</u> Centre on LinkedIn

Register with (1) UK PharmaScan

Keep AWTTC informed of new pipeline medicines

Come and talk with the team about how we can improve our engagement with industry

Feedback and test our company pro-forma



Medicines access



Medicines value unit



National prescribing indicators

### Mini Networking Sessions



Medicines Optimisation





**Company engagement** 

### Diolch yn fawr Thank you

https://awttc.nhs.wales

https://cttcg.gig.cymru

@AWTTCcomms

@AWTTCcymraeg



@AWTTC - All Wales Therapeutics & Toxicology Centre